Karo Pharma Smart choices for everyday healthcare About Products Karo Everyday Investors News & Press English Repurchased shares According to announcement on 30th of July, 2018, the Board of Directors in Karo Pharma has decided on a repurchase program of own shares. A maximum of 2 464 990 shares may be acquired for a total value of maximum 86,3 MSEK during the period until 31st of August, 2018. Below report provides an overview of the repurchase program. By end of 27 July 2018 a total of 2,464,990 shares has been repurchased. This repurchase program is thereby completed and closed. Date Aggregated daily volume (number of shares) Weighted average share price per day (SEK) Total daily transaction value (SEK) 18 June 2018 107 200 29,640365 3 177 447 19 June 2018 89 250 29,363100 2 620 657 20 June 2018 86 839 29,366600 2 550 166 21 June 2018 100 000 29,360800 2 936 080 25 June 2018 104 906 29,278900 125 045 26 June 2018 100 000 29,206900 2 920 690 27 June 2018 78 000 29,595300 2 308 433 28 June 2018 98 332 29,657800 2 916 311 29 June 2018 79 578 29,621200 2 357 196 2 July 2018 76 415 29,625600 2 263 840 3 July 2018 65 862 29,671200 1 954 205 4 July 2018 73 522 29,641600 2 179 310 5 July 2018 80 000 29,644500 2 371 560 6 July 2018 69 425 29,819400 2 070 212 9 July 2018 65 500 31,384700 2 055 698 10 July 2018 80 000 32,030000 2 562 400 11 July 2018 81 562 31,871700 2 599 520 12 July 2018 80 000 32,115600 2 569 248 13 July 2018 80 000 32,093300 2 567 464 16 July 2018 80 000 32,107000 2 568 560 17 July 2018 90 000 31,987100 2 878 839 18 July 2018 71 063 32,614000 2 317 649 19 July 2018 120 000 32,499900 3 899 988 20 July 2018 80 000 32,479500 2 598 360 23 July 2018 71 171 33,345000 2 373 197 24 July 2018 84 680 33,693700 2 853 183 25 July 2018 82 176 33,720700 2 771 032 26 July 2018 90 000 34,346700 3 091 203 27 July 2018 99 509 34,873300 3 470 207 A full breakdown of the transactions pursuant to article 5.3 of MAR and article 2.3 of the Safe Harbour Regulation is available in below document. Related documents Document Products Financial reports Financial Press releases Contact Karo Pharma Follow us on LinkedIn Copyright© Karo Pharma AB 2021 Cookies are required for our website to function optimally and to improve the user experience. By browsing further, you accept our use of cookies.» Privacy policy Approve